USD 14.03
| ticker | 1 day return % | 1 week return % | 1 month return % | 3 months return % | 6 months return % | 1 year return % | 3 years return % | 5 years return % | 10 years return % | maximum return % |
|---|---|---|---|---|---|---|---|---|---|---|
| RCUS | -0.6 | -4.0 | -12.7 | -23.1 | -9.4 | -17.5 | -59.2 | 37.1 | -17.5 | -17.5 |
| S&P 500 | 1.0 | 1.8 | -0.9 | 2.7 | 7.3 | 26.5 | 31.0 | 80.1 | 196.5 | 33856.2 |
Our interactive price chart includes various drawing tools to help you analyze the product more effectively. Below is a quick guide on how to use these tools: Full Guideline
Feel free to experiment with these tools to enhance your technical analysis. Remember, any drawings you make are temporary and will be lost upon refreshing the page unless saved as an image using the 'Camera' icon.
Get instant AI-powered professional insights on prices:
💡Generate AI Technical Analysis ReportA Multi-Interval Candlestick Chart displays the price movements of an asset over different time intervals. Each candlestick represents the open, high, low, and close prices for a specific interval. The chart can be used to identify trends and patterns in price movements.
| Attribute | Value |
|---|---|
| symbol | RCUS |
| name | Arcus Biosciences, Inc. |
| price | 14.03 |
| changes percentage | -0.6374 |
| change | -0.09 |
| day low | 13.95 |
| day high | 14.4499 |
| year high | 20.31 |
| year low | 13.51 |
| market cap | 1283907748 |
| price avg 50 | 15.689 |
| price avg 200 | 15.9909 |
| exchange | NYSE |
| volume | 255555 |
| avg volume | 735378 |
| open | 14.31 |
| previous close | 14.12 |
| eps | -3.19 |
| pe | -4.4 |
| earnings announcement | 2025-02-19T10:59:00.000+0000 |
| shares outstanding | 91511600 |
| timestamp | 2025-01-17 21:00:02 |
We derive the score of a company's financial statements by evaluating the weighted average sentiment across key within the statements. The cumulative score, normalized to a sum of 1, serves as a metric for assessing the company's performance during the specified period. A higher score indicates stronger performance. However, it's crucial to note that while this score provides valuable insights, it is just one of many factors to consider when making informed investment decisions. A holistic evaluation, considering various aspects of the company's financial health and market conditions, is essential for a well-rounded investment strategy.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001724521 | |||
| revenue | 117000000 | 112000000 | 4.46 |
| gross profit | -223000000 | 98000000 | -327.55 |
| gross profit ratio | -1.91 | 0.88 | -317.83 |
| research and development expenses | 340000000 | 288000000 | 18.06 |
| operating expenses | 457000000 | 392000000 | 16.58 |
| interest income | 41000000 | 16000000 | 156.25 |
| interest expense | 2000000 | 2000000 | 0.00 |
| ebitda | -283000000 | -250000000 | -13.20 |
| ebitdaratio | -2.42 | -2.36 | -2.62 |
| operating income | -340000000 | -280000000 | -21.43 |
| operating income ratio | -2.91 | -2.5 | -16.24 |
| net income | -307000000 | -267000000 | -14.98 |
| net income ratio | -2.62 | -2.38 | -10.07 |
| eps | -4.15 | -3.71 | -11.86 |
Revenue Growth: revenue increased to 117 million in 2023 from 112 million in 2022 representing a change of 4.46%. This indicates a sales growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 340 million in 2023 from 288 million in 2022 representing a change of 18.06%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased to -283 million in 2023 from -250 million in 2022 representing a change of -13.2%. The increase in EBITDA indicates improved operational efficiency and profitability.
Operating Income: Operating income increased to -340 million in 2023 from -280 million in 2022 representing a change of -21.43%. The increase in operating income indicates better operational performance and increased profitability.
Net Income: Net income increased to -307 million in 2023 from -267 million in 2022 representing a change of -14.98%. The increase in net income shows improved profitability and indicates that the company is generating more profit for each dollar of revenue.
Gross Profit: Gross Profit decreased to -223 million in 2023 from 98 million in 2022 representing a change of -327.55%. This indicates a sales profitability decline, which is a negative sign for the company.
Operating Expenses: Operating Expenses increased to 457 million in 2023 from 392 million in 2022 representing a change of 16.58%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
Earnings per Share (EPS): EPS increased to -4.15 in 2023 from -4.15 in 2022 representing a change of -11.86%. This indicates that the company's earnings are decreasing and it is becoming less profitable on a per-share basis.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001724521 | |||
| revenue | 48000000 | 39000000 | 23.08 |
| gross profit | 48000000 | 37000000 | 29.73 |
| gross profit ratio | 1 | 0.95 | 5.41 |
| research and development expenses | 123000000 | 115000000 | 6.96 |
| operating expenses | 153000000 | 143000000 | 6.99 |
| interest income | 14000000 | 13000000 | 7.69 |
| interest expense | 1000000 | 0 | NaN |
| ebitda | -89000000 | -91000000 | 2.20 |
| ebitdaratio | -1.85 | -2.67 | 30.47 |
| operating income | -105000000 | -106000000 | 0.94 |
| operating income ratio | -2.19 | -2.72 | 19.52 |
| net income | -92000000 | -93000000 | 1.08 |
| net income ratio | -1.92 | -2.38 | 19.62 |
| eps | -1.01 | -1.02 | 0.98 |
Revenue Growth: revenue increased to 48 million in 2024Q3 from 39 million in 2024Q2 representing a change of 23.08%. This indicates a sales growth, which is a positive sign for the company.
Gross Profit: Gross Profit increased to 48 million in 2024Q3 from 37 million in 2024Q2 representing a change of 29.73%. This indicates a sales profitability growth, which is a positive sign for the company.
Research and Development (R&D) Expenses: R&D Expenses increased to 123 million in 2024Q3 from 115 million in 2024Q2 representing a change of 6.96%. This shows that the company continues to invest in innovation and product development, which is crucial for long-term growth.
Earnings per Share (EPS): EPS increased to -1.01 in 2024Q3 from -1.01 in 2024Q2 representing a change of 0.98%. This indicates that the company's earnings are increasing and it is becoming more profitable on a per-share basis.
Operating Expenses: Operating Expenses increased to 153 million in 2024Q3 from 143 million in 2024Q2 representing a change of 6.99%. The increase in operating expenses can be attributed to various factors such as marketing, administrative costs, and investments in infrastructure. It's important to monitor if these expenses are growing at a sustainable rate compared to revenue.
EBITDA: EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to -89 million in 2024Q3 from -91 million in 2024Q2 representing a change of 2.2%. The decrease in EBITDA indicates declined operational efficiency and profitability.
Operating Income: Operating income decreased to -105 million in 2024Q3 from -106 million in 2024Q2 representing a change of 0.94%. The decrease in operating income indicates worse operational performance and decreased profitability.
Net Income: Net income decreased to -92 million in 2024Q3 from -93 million in 2024Q2 representing a change of 1.08%. The decrease in net income shows worsen profitability and indicates that the company is generating less profit for each dollar of revenue.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001724521 | |||
| total assets | 1095000000 | 1345000000 | -18.59 |
| total liabilities | 633000000 | 688000000 | -7.99 |
| total equity | 462000000 | 657000000 | -29.68 |
| cash and cash equivalents | 127000000 | 206000000 | -38.35 |
| short term investments | 632000000 | 803000000 | -21.30 |
| long term investments | 107000000 | 129000000 | -17.05 |
| total current assets | 831000000 | 1067000000 | -22.12 |
| total non current assets | 264000000 | 278000000 | -5.04 |
| total current liabilities | 184000000 | 193000000 | -4.66 |
| total non current liabilities | 449000000 | 495000000 | -9.29 |
| common stock | 1311000000 | 1206000000 | 8.71 |
| retained earnings | -849000000 | -542000000 | -56.64 |
| total debt | 11000000 | 120000000 | -90.83 |
Total Assets: Total Assets decreased to 1,095 million in 2023 from 1,345 million in 2022 representing a change of -18.59%. Suggesting a decrease in asset holdings.
Total Equity: Total Equity decreased to 462 million in 2023 from 657 million in 2022 representing a change of -29.68%. This indicates a decrease in shareholders' equity.
Cash And Cash Equivalents: Cash And Cash Equivalents decreased to 127 million in 2023 from 206 million in 2022 representing a change of -38.35%. This indicates a decrease in available liquid assets.
Short Term Investments: Short Term Investments decreased to 632 million in 2023 from 803 million in 2022 representing a change of -21.3%. This indicates a decrease in short-term investment holdings.
Total Current Assets: Total Current Assets decreased to 831 million in 2023 from 1,067 million in 2022 representing a change of -22.12%. This indicates a worsen liquidity position.
Retained Earnings: Retained Earnings decreased to -849 million in 2023 from -542 million in 2022 representing a change of -56.64%. This indicates an accumulated losses.
Total Liabilities: Total Liabilities decreased to 633 million in 2023 from 688 million in 2022 representing a change of -7.99%. This indicates a decrease in overall liabilities.
Total Current Liabilities: Total Current Liabilities decreased to 184 million in 2023 from 193 million in 2022 representing a change of -4.66%. This indicates a lower short-term debt burden.
Common Stock: Common Stock increased to 1,311 in 2023 from 1,206 in 2022 representing a change of 8.71%. This indicates an increase in ownership interest.
Total Debt: Total Debt decreased to 11 million in 2023 from 120 million in 2022 representing a change of -90.83%. This indicates a reduction in overall debt burden.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001724521 | |||
| total assets | 1252000000 | 1186000000 | 5.56 |
| total liabilities | 687000000 | 551000000 | 24.68 |
| total equity | 565000000 | 635000000 | -11.02 |
| cash and cash equivalents | 201000000 | 156000000 | 28.85 |
| short term investments | 888000000 | 813000000 | 9.23 |
| long term investments | 2000000 | 49000000 | -95.92 |
| total current assets | 1127000000 | 1022000000 | 10.27 |
| total non current assets | 125000000 | 164000000 | -23.78 |
| total current liabilities | 215000000 | 199000000 | 8.04 |
| total non current liabilities | 472000000 | 352000000 | 34.09 |
| common stock | 1602000000 | 1582000000 | 1.26 |
| retained earnings | -1038000000 | -946000000 | -9.73 |
| total debt | 58000000 | 11000000 | 427.27 |
Total Assets: Total Assets increased to 1,252 million in 2024Q3 from 1,186 million in 2024Q2 representing a change of 5.56%. Suggesting a growth in asset holdings.
Cash And Cash Equivalents: Cash And Cash Equivalents increased to 201 million in 2024Q3 from 156 million in 2024Q2 representing a change of 28.85%. This indicates an increase in available liquid assets.
Short Term Investments: Short Term Investments increased to 888 million in 2024Q3 from 813 million in 2024Q2 representing a change of 9.23%. This indicates an increase in short-term investment holdings.
Total Current Assets: Total Current Assets increased to 1,127 million in 2024Q3 from 1,022 million in 2024Q2 representing a change of 10.27%. This indicates a better liquidity position.
Common Stock: Common Stock increased to 1,602 in 2024Q3 from 1,582 in 2024Q2 representing a change of 1.26%. This indicates an increase in ownership interest.
Total Liabilities: Total Liabilities increased to 687 million in 2024Q3 from 551 million in 2024Q2 representing a change of 24.68%. This indicates an increase in overall liabilities.
Total Equity: Total Equity decreased to 565 million in 2024Q3 from 635 million in 2024Q2 representing a change of -11.02%. This indicates a decrease in shareholders' equity.
Total Current Liabilities: Total Current Liabilities increased to 215 million in 2024Q3 from 199 million in 2024Q2 representing a change of 8.04%. This indicates a higher short-term debt burden.
Retained Earnings: Retained Earnings decreased to -1,038 million in 2024Q3 from -946 million in 2024Q2 representing a change of -9.73%. This indicates an accumulated losses.
Total Debt: Total Debt increased to 58 million in 2024Q3 from 11 million in 2024Q2 representing a change of 427.27%. This indicates an increase in overall debt burden.
| 2023 | 2022 | Y/Y change % | |
|---|---|---|---|
| 0001724521 | |||
| net change in cash | -79000000 | 58000000 | -236.21 |
| operating cash flow | -306000000 | 438000000 | -169.86 |
| free cash flow | -330000000 | 426000000 | -177.46 |
| capital expenditure | -24000000 | -12000000 | -100.00 |
| depreciation and amortization | 8000000 | 6000000 | 33.33 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 73000000 | 65000000 | 12.31 |
| accounts payables | -1000000 | 8000000 | -112.50 |
| inventory | 0 | -704000000 | 100.00 |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -24000000 | -12000000 | -100.00 |
| net cash used for investing activites | 194000000 | -413000000 | 146.97 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | 25000000 | 23000000 | 8.70 |
| common stock repurchased | 0 | 0 | NaN |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 33000000 | 33000000 | 0.00 |
| cash at end of period | 130000000 | 209000000 | -37.80 |
| accounts receivables | 15000000 | 704000000 | -97.87 |
| cash at beginning of period | 209000000 | 151000000 | 38.41 |
Net Change in Cash: Net Change in Cash decreased to -79 million in 2023 from 58 million in 2022 representing a change of -236.21%. Indicating a declined ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow decreased to -306 million in 2023 from 438 million in 2022 representing a change of -169.86%. This indicates that the company generated less cash from its core business operations.
Free Cash Flow: Free Cash Flow decreased to -330 million in 2023 from 426 million in 2022 representing a change of -177.46%. This indicates a decrease in cash generated after accounting for capital expenditures.
Stock-Based Compensation: Stock-Based Compensation increased to 73 million in 2023 from 65 million in 2022 representing a change of 12.31%. This indicates increased expenses, which is generally considered a negative sign from a financial perspective.
Capital Expenditure: Capital Expenditure decreased to -24 million in 2023 from -12 million in 2022 representing a change of -100.0%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Accounts Payables: The absolute value of Accounts Payables decreased to 1 million in 2023 from 8 million in 2022 representing a change of -112.5%. This indicates that the company has reduced its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables decreased to 15 million in 2023 from 704 million in 2022 representing a change of -97.87%. This suggests that the company has been able to collect payments from its customers more efficiently and timely.
| 2024Q3 | 2024Q2 | Q/Q change % | |
|---|---|---|---|
| 0001724521 | |||
| operating cash flow | 26000000 | -94000000 | 127.66 |
| free cash flow | 25000000 | -94000000 | 126.60 |
| capital expenditure | -1000000 | 0 | NaN |
| depreciation and amortization | 2000000 | 2000000 | 0.00 |
| deferred income tax | 0 | 0 | NaN |
| stock based compensation | 19000000 | 20000000 | -5.00 |
| accounts receivables | 12000000 | 7000000 | 71.43 |
| accounts payables | -1000000 | 0 | NaN |
| inventory | 0 | 0 | NaN |
| acquisitions net | 0 | 0 | NaN |
| investments in property plant and equipment | -1000000 | 0 | NaN |
| net cash used for investing activites | -29000000 | 63000000 | -146.03 |
| debt repayment | 0 | 0 | NaN |
| common stock issued | -3000000 | 3000000 | -200.00 |
| common stock repurchased | 1000000 | -1000000 | 200.00 |
| dividends paid | 0 | 0 | NaN |
| net cash used provided by financing activities | 48000000 | 2000000 | 2300.00 |
| net change in cash | 45000000 | -29000000 | 255.17 |
| cash at end of period | 204000000 | 156000000 | 30.77 |
| cash at beginning of period | 159000000 | 185000000 | -14.05 |
Net Change in Cash: Net Change in Cash increased to 45 million in 2024Q3 from -29 million in 2024Q2 representing a change of 255.17%. Indicating an increased ability to generate cash from the company's operations or its cash flow position.
Operating Cash Flow: Operating Cash Flow increased to 26 million in 2024Q3 from -94 million in 2024Q2 representing a change of 127.66%. This indicates that the company generated more cash from its core business operations.
Free Cash Flow: Free Cash Flow increased to 25 million in 2024Q3 from -94 million in 2024Q2 representing a change of 126.6%. This indicates an increase in cash generated after accounting for capital expenditures.
Capital Expenditure: Capital Expenditure decreased to -1 million in 2024Q3 from 0 million in 2024Q2 representing a change of nan%. This indicates a possible improved efficiency or a shift in the company's strategic priorities.
Stock-Based Compensation: Stock-Based Compensation decreased to 19 million in 2024Q3 from 20 million in 2024Q2 representing a change of -5.0%. This indicates decreased expenses, which is generally considered a positive sign from a financial perspective.
Accounts Payables: The absolute value of Accounts Payables increased to 1 million in 2024Q3 from 0 million in 2024Q2 representing a change of nan%. This indicates that the company has increased its outstanding obligations to its suppliers.
Accounts Receivables: Accounts Receivables increased to 12 in 2024Q3 from 7 million in 2024Q2 representing a change of 71.43%. This suggests that the company is less capable of collecting payments from its customers.
We save you time by utilizing Generative AI to summarize earnings transcripts. Our summaries provide a clear insight into the company's current performance, future outlook, and overall sentiment expressed during the call. Click on below links to explore more.
Note: The years mentioned below are fiscal years in accounting.
Q3 2024 Earnings call transcript
EPS represents the portion of a company's profit allocated to each outstanding share of common stock. A higher EPS is generally favorable, indicating stronger profitability on a per-share basis.
Positive EPS: A positive EPS signifies that a company is profitable, it is generally viewed positively, supporting stock value and investor confidence.
Negative EPS: Indicates that a company is operating at a loss, which could lead to negative sentiment, potential stock depreciation, and concerns about the company's financial health.
The Next Earning Date represents when the company plans to release its next set of financial results.
An upward trend in EPS suggests consistent growth in earnings, often leading to increased investor confidence. A downward trend may indicate a decline in earnings, potentially decreasing investor confidence and stock value. Fluctuating EPS suggests unpredictable financial performance, warranting cautious investor analysis.
Earnings surprise occurs when a company's actual earnings differ from analysts' expectations. A positive earnings surprise typically reflects better-than-expected performance, potentially leading to stock appreciation. Conversely, a negative earnings surprise can result in stock depreciation. An earnings surprise of zero means the earnings met expectations, which typically has a neutral impact on stock price.
Discover detailed analyst recommendations for stocks, including categories such as Buy, Hold, Sell, Strong Buy, and Strong Sell. These insights are based on thorough analysis of financial and market factors. The consensus is calculated by assigning a numerical score to each recommendation. These scores are then weighted and averaged over a specified period to provide a comprehensive view of the stock's outlook, with the final score determining the overall consensus.
| 2023-12-31 | 2022-12-31 | Y/Y change % | |
|---|---|---|---|
| FY | |||
| calendar year | 2023 | 2022 | NaN |
| revenue per share | 1.58 | 1.56 | 1.64 |
| net income per share | -4.15 | -3.71 | -11.87 |
| operating cash flow per share | -4.14 | 6.08 | -167.97 |
| free cash flow per share | -4.46 | 5.92 | -175.37 |
| cash per share | 10.26 | 14.01 | -26.81 |
| book value per share | 6.24 | 9.12 | -31.58 |
| tangible book value per share | 6.24 | 9.12 | -31.58 |
| shareholders equity per share | 6.24 | 9.12 | -31.58 |
| interest debt per share | 0.18 | 1.69 | -89.63 |
| market cap | 1413400000 | 1488960000 | -5.07 |
| enterprise value | 1297400000 | 1402960000 | -7.52 |
| pe ratio | -4.6 | -5.58 | 17.44 |
| price to sales ratio | 12.08 | 13.29 | -9.13 |
| pocfratio | -4.62 | 3.4 | -235.87 |
| pfcf ratio | -4.28 | 3.5 | -222.54 |
| pb ratio | 3.06 | 2.27 | 34.99 |
| ptb ratio | 3.06 | 2.27 | 34.99 |
| ev to sales | 11.09 | 12.53 | -11.48 |
| enterprise value over ebitda | -4.58 | -5.61 | 18.31 |
| ev to operating cash flow | -4.24 | 3.2 | -232.37 |
| ev to free cash flow | -3.93 | 3.29 | -219.38 |
| earnings yield | -0.22 | -0.18 | -21.13 |
| free cash flow yield | -0.23 | 0.29 | -181.61 |
| debt to equity | 0.02 | 0.18 | -86.96 |
| debt to assets | 0.01 | 0.09 | -88.74 |
| net debt to ebitda | 0.41 | 0.34 | 19.16 |
| current ratio | 4.52 | 5.53 | -18.31 |
| interest coverage | -170 | -140 | -21.43 |
| income quality | 1.0 | -1.64 | 160.76 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 1 | 0.93 | 7.69 |
| research and ddevelopement to revenue | 2.91 | 2.57 | 13.01 |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | -0.08 | 0.03 | -386.27 |
| capex to revenue | 0.21 | 0.11 | 91.45 |
| capex to depreciation | 3 | 2 | 50.00 |
| stock based compensation to revenue | 0.62 | 0.58 | 7.51 |
| graham number | 24.14 | 27.59 | -12.51 |
| roic | -0.38 | -0.24 | -54.57 |
| return on tangible assets | -0.28 | -0.2 | -41.23 |
| graham net net | 2.13 | 3.71 | -42.66 |
| working capital | 647000000 | 874000000 | -25.97 |
| tangible asset value | 462000000 | 657000000 | -29.68 |
| net current asset value | 198000000 | 379000000 | -47.76 |
| invested capital | 698000000 | 909000000 | -23.21 |
| average receivables | 42500000 | 394000000 | -89.21 |
| average payables | 18500000 | 15130500 | 22.27 |
| average inventory | -86000000 | -467221000 | 81.59 |
| days sales outstanding | 131.03 | 140.13 | -6.50 |
| days payables outstanding | 18.25 | 521.43 | -96.50 |
| days of inventory on hand | 0 | -4484.29 | 100.00 |
| receivables turnover | 2.79 | 2.6 | 6.95 |
| payables turnover | 20 | 0.7 | 2757.14 |
| inventory turnover | 0 | -0.08 | 100.00 |
| roe | -0.66 | -0.41 | -63.51 |
| capex per share | 0.32 | 0.17 | 94.59 |
ROE: Return on Equity (ROE) decreased to -0.66 on 2023-12-31 from -0.41 on 2022-12-31, representing a change of -63.51%. Suggesting that the company has not been generating high returns for its shareholders.
Current Ratio: Current Ratio decreased to 4.52 on 2023-12-31 from 5.53 on 2022-12-31, representing a change of -18.31%. The current ratio has been declining, suggesting a decrease in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
PE Ratio: Price-to-Earnings (P/E) Ratio increased to -4.60 on 2023-12-31 from -5.58 on 2022-12-31, representing a change of 17.44%. Indicating an increase in the relative valuation of the company's stock.
Debt-to-Equity Ratio: Debt-to-Equity Ratio decreased to 0.02 on 2023-12-31 from 0.18 on 2022-12-31, representing a change of -86.96%. The debt-to-equity ratio has been decreasing, indicating that the company has been relying less on debt financing. A ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
| 2024-09-30 Q3 | 2024-06-30 Q2 | Q/Q change % | |
|---|---|---|---|
| RCUS | |||
| calendar year | 2024 | 2024 | NaN |
| revenue per share | 0.53 | 0.43 | 22.67 |
| net income per share | -1.01 | -1.02 | 1.40 |
| operating cash flow per share | 0.28 | -1.03 | 127.57 |
| free cash flow per share | 0.27 | -1.03 | 126.51 |
| cash per share | 11.91 | 10.64 | 12.02 |
| book value per share | 6.18 | 6.97 | -11.32 |
| tangible book value per share | 6.18 | 6.97 | -11.32 |
| shareholders equity per share | 6.18 | 6.97 | -11.32 |
| interest debt per share | 0.65 | 0.12 | 434.60 |
| market cap | 1397506000 | 1393830000 | 0.26 |
| enterprise value | 1254506000 | 1248830000 | 0.45 |
| pe ratio | -3.8 | -3.75 | -1.35 |
| price to sales ratio | 29.11 | 35.74 | -18.54 |
| pocfratio | 53.75 | -14.83 | 462.49 |
| pfcf ratio | 55.9 | -14.83 | 476.99 |
| pb ratio | 2.47 | 2.2 | 12.69 |
| ptb ratio | 2.47 | 2.2 | 12.69 |
| ev to sales | 26.14 | 32.02 | -18.38 |
| enterprise value over ebitda | -14.1 | -13.72 | -2.71 |
| ev to operating cash flow | 48.25 | -13.29 | 463.18 |
| ev to free cash flow | 50.18 | -13.29 | 477.71 |
| earnings yield | -0.07 | -0.07 | 1.34 |
| free cash flow yield | 0.02 | -0.07 | 126.53 |
| debt to equity | 0.1 | 0.02 | 492.60 |
| debt to assets | 0.05 | 0.01 | 399.48 |
| net debt to ebitda | 1.61 | 1.59 | 0.84 |
| current ratio | 5.24 | 5.14 | 2.07 |
| interest coverage | -105 | 0 | NaN |
| income quality | -0.28 | 1.01 | -127.96 |
| dividend yield | 0 | 0 | NaN |
| payout ratio | 0 | 0 | NaN |
| sales general and administrative to revenue | 0.62 | 0.77 | -18.75 |
| research and ddevelopement to revenue | 2.56 | 2.95 | -13.10 |
| intangibles to total assets | 0 | 0 | NaN |
| capex to operating cash flow | 0.04 | 0 | NaN |
| capex to revenue | 0.02 | 0 | NaN |
| capex to depreciation | 0.5 | 0 | NaN |
| stock based compensation to revenue | 0.4 | 0.51 | -22.81 |
| graham number | 11.83 | 12.65 | -6.49 |
| roic | -0.1 | -0.11 | 5.67 |
| return on tangible assets | -0.07 | -0.08 | 6.29 |
| graham net net | 4.57 | 4.86 | -5.96 |
| working capital | 912000000 | 823000000 | 10.81 |
| tangible asset value | 565000000 | 635000000 | -11.02 |
| net current asset value | 440000000 | 471000000 | -6.58 |
| invested capital | 960000000 | 872000000 | 10.09 |
| average receivables | 27000000 | 36500000 | -26.03 |
| average payables | 14000000 | 15500000 | -9.68 |
| average inventory | 0 | 0 | NaN |
| days sales outstanding | 39.38 | 76.15 | -48.30 |
| days payables outstanding | 0 | 675 | -100.00 |
| days of inventory on hand | 0 | 0 | NaN |
| receivables turnover | 2.29 | 1.18 | 93.41 |
| payables turnover | 0 | 0.13 | -100.00 |
| inventory turnover | 0 | 0 | NaN |
| roe | -0.16 | -0.15 | -11.18 |
| capex per share | 0.01 | 0 | NaN |
ROE: Return on Equity (ROE) decreased to -0.16 on 2024-09-30 Q3 from -0.15 on 2024-06-30 Q2, representing a change of -11.18%. Suggesting that the company has not been generating high returns for its shareholders.
PE Ratio: Price-to-Earnings (P/E) Ratio decreased to -3.80 on 2024-09-30 Q3 from -3.75 on 2024-06-30 Q2, representing a change of -1.35%. Indicating a decrease in the relative valuation of the company's stock.
Current Ratio: Current Ratio increased to 5.24 on 2024-09-30 Q3 from 5.14 on 2024-06-30 Q2, representing a change of 2.07%. The current ratio has been increasing, suggesting an increase in the company's short-term liquidity. Since it's above 3, indicating poor management of working capital.
Debt-to-Equity Ratio: Debt-to-Equity Ratio increased to 0.10 on 2024-09-30 Q3 from 0.02 on 2024-06-30 Q2, representing a change of 492.60%. The debt-to-equity ratio has been increasing, indicating that the company has been relying more on debt financing. Higher leverage may increase financial risk. However, a ratio of 1 or below is often considered healthy and indicates that the company's total debt is equal to or less than its total equity.
None
| Market Capitalization | Enterprise Value | |
|---|---|---|
| Definition | The total market value of a company's outstanding shares | The total market value of a company, including its debt and other liabilities |
| Calculation | Current share price * Total number of outstanding shares | Market capitalization + Total debt - Cash and cash equivalents |
| Focus | Equity component of a company's value | Total economic value of a company |
| Usefulness | Assesses a company's size and growth potential based on investor sentiment | Provides a more comprehensive valuation that considers both equity and debt |
Analyzing dividends is a crucial aspect of investment evaluation, offering valuable insights into a company's financial health and its commitment to shareholder returns. Dividends represent a portion of a company's profits distributed to its shareholders, providing a steady income stream. We help you analyze dividends based on the indicators mentioned below:
• Investors often assess the average dividend amount, observing trends over time to gauge the company's stability and growth potential. A positive trend in average dividends indicates a consistent and potentially lucrative investment. Additionally, evaluating the trend of dividend increases provides insight into the company's financial strength and management's confidence in future earnings.
• Consistency in paying dividends is a reassuring sign, reflecting a company's reliability and commitment to shareholder value. For investors, dividends not only offer income but also contribute to the overall total return on investment.
• Companies with a history of regular and increasing dividends can attract income-focused investors seeking stable returns, making dividends a critical factor in building a well-rounded investment portfolio.
Interested in the overall sentiment for a particular period? Check out our news sentiment analysis tool.
Sentiment: Positive
Publish Date: 2025-01-14 22:51:59
Arcus Biosciences has interesting combination therapies that target several diseases like NSCLC, RCC, GI, and pancreatic cancers. The company has a few ongoing Phase 3 trials, some of which will report important updates in 2025. One of Domvanalimab's combinations showed that it can help overall survival by a whopping 36% in NSCLC. It also had lower discontinuation rates than chemotherapy.
Sentiment: Positive
Publish Date: 2025-01-13 08:00:00
Arcus Biosciences presents a strong buying opportunity due to positive data, Gilead's increased stake, and a robust pipeline with significant market potential. Lead molecule domvanalimab shows promising phase 3 trial results in lung and gastrointestinal cancers, with substantial survival benefits and market potential of $10bn. Casdatifan, an HIF-2α inhibitor, has shown superior data in clear cell renal cell carcinoma, positioning it as a leading candidate in a $2bn market.
Sentiment: Positive
Publish Date: 2024-12-24 16:05:00
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted four new employees options to purchase a total of 66,900 shares of the Company's common stock at an exercise price per share of $15.96, which was the closing price on December 23, 2024,.
Sentiment: Negative
Publish Date: 2024-12-19 16:05:00
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that Terry Rosen, Ph.D., chief executive officer, will present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The presentation will take place on Tuesday, January 14th, 2025, at 3:45pm PT. A live webcast of the presentation will be avail.
Sentiment: Positive
Publish Date: 2024-12-10 16:35:00
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted two new employees options to purchase a total of 7,400 shares of the Company's common stock at an exercise price per share of $17.47 which was the closing price on December 9, 2024, and.
Sentiment: Positive
Publish Date: 2024-12-03 16:35:00
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted three new employees options to purchase a total of 10,000 shares of the Company's common stock at an exercise price per share of $14.56, which was the closing price on November 25, 2024,.
Sentiment: Negative
Publish Date: 2024-11-19 16:05:00
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in December: Evercore 7th Annual HealthCONx Conference Date: Tuesday, December 3rd, 2024 Location: Coral Gables, FL Format: Fireside chat & 1x1 meetings Time: 7:55 a.m. ET Citi 2024.
Sentiment: Positive
Publish Date: 2024-11-12 16:35:00
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted four new employees options to purchase a total of 14,100 shares of the Company's common stock at an exercise price per share of $17.85, which was the closing price on November 8, 2024, and.
Sentiment: Negative
Publish Date: 2024-11-06 18:41:20
Arcus Biosciences, Inc. (RCUS) came out with a quarterly loss of $1 per share versus the Zacks Consensus Estimate of a loss of $1.07. This compares to loss of $0.94 per share a year ago.
Sentiment: Negative
Publish Date: 2024-11-06 16:22:00
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today reported financial results for the third quarter ended September 30, 2024, and provided a pipeline update on its clinical-stage investigational molecules — targeting TIGIT, HIF-2a, CD73, the A2a/A2b receptors, CD-39, AXL and PD-1 — across multiple common cancers. “Through.
Sentiment: Positive
Publish Date: 2024-10-24 16:35:00
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted six new employees options to purchase a total of 28,600 shares of the Company's common stock at an exercise price per share of $17.33, which was the closing price on October 23, 2024, and.
Sentiment: Negative
Publish Date: 2024-10-24 07:30:00
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today presented the first clinical activity data for casdatifan, a HIF-2a inhibitor with best-in-class potential, in an oral plenary session by Dr. Toni K. Choueiri, Dana-Farber Cancer Institute at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics i.
Sentiment: Neutral
Publish Date: 2024-10-22 16:05:00
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will host a conference call and webcast on Wednesday, November 6th, 2024 at 2 PM PT / 5 PM ET to discuss details of the Company's financial results and pipeline update for the quarter ended September 30th, 2024. Investors interested in listening to.
* The sentiment analysis presented is generated through an algorithm and may be subject to inaccuracies. Users are advised to corroborate key information and employ further analytical methods prior to making critical decisions.
Get instant AI-powered professional insights:
💡Generate AI Technical Analysis ReportUnderstand the chart below:
Interpret Technical Indicators
| Indicator | Bullish | Bearish |
|---|---|---|
| Price and EMA ⓘ | Price crosses above EMA | Price crosses below EMA |
| Short-Term vs Long-Term EMA ⓘ | Short EMA crosses above Long EMA | Short EMA crosses below Long EMA |
| Volume ⓘ | Increasing volume during price uptrend | Increasing volume during price downtrend |
| MACD ⓘ | MACD crosses above Signal Line | MACD crosses below Signal Line |
| RSI ⓘ | RSI is below 30 (oversold) and starts to rise above 30 | RSI is above 70 (overbought) and starts to decline below 70 |
| Candlestick Patterns ⓘ | Bullish candlestick patterns | Bearish candlestick patterns |
Copyright © 2024 Sirius Investors
All rights reserved
